TaiRx

TaiRx Equity

The The Equity of TaiRx (6580.TWO) as of Oct 18, 2026 is 441.59 M TWD. In the previous year, The Equity was 647.17 M TWD — a change of -31.77% (lower).

Equity

441.59 MTWD

YoY

-31.77%

Last updated:

In 2025, TaiRx's equity was 441.59 M TWD, a -31.77% increase from the 647.17 M TWD equity in the previous year.

The TaiRx Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
590.00 M TWD
Jan 1, 2019
451.25 M TWD
Jan 1, 2020
788.71 M TWD
Jan 1, 2021
674.56 M TWD
Jan 1, 2022
477.79 M TWD
Jan 1, 2023
771.80 M TWD
Jan 1, 2024
647.17 M TWD
Jan 1, 2025
441.59 M TWD
The TaiRx Equity history
YEAREquityYoY
441.59 MTWD-31.77%
647.17 MTWD-16.15%
771.80 MTWD+61.53%
477.79 MTWD-29.17%
674.56 MTWD-14.47%
788.71 MTWD+74.78%
451.25 MTWD-23.52%
590.00 MTWD-25.98%
797.09 MTWD-13.50%
921.45 MTWD+15.35%
798.86 MTWD-10.12%
888.84 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TaiRx Stock analysis

What does TaiRx do? TaiRx Inc, listed on the Taiwan Stock Exchange under ticker 6580.TWO with ISIN TW0006580004, is a biotechnology company based in Taipei City, Taiwan. The company operates within the Health Care sector, focusing on research and development of novel drug products for cancer treatment. TaiRx went public through an IPO on June 20, 2017. Its primary focus includes the development of cancer treatment drugs and sepsis adjuvant therapy drugs. The company's product portfolio includes CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, and TRX-105. Among these, CVM-1118 and Rexis are currently in clinical trials. Zelnite is distributed to domestic medical institutions at all levels through distributors. TaiRx maintains a corporate website at https://www.trx.com.tw/, where further information about its operations and products can be found. The company is engaged in the research and development of innovative pharmaceutical solutions, targeting significant unmet medical needs in oncology and sepsis treatment. TaiRx's activities are centered on advancing drug candidates through clinical development and commercialization within the Taiwanese market and potentially beyond. The company's operations are conducted from its headquarters in Taipei City, reflecting its commitment to contributing to the healthcare industry in Taiwan and globally. TaiRx is one of the most popular companies on Eulerpool.

Equity Details

Analyzing TaiRx's Equity

TaiRx's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding TaiRx's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating TaiRx's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

TaiRx's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in TaiRx’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about TaiRx stock

The Equity of TaiRx is 441.59 M TWD in 2025.

The Equity of TaiRx changed from 647.17 M TWD to 441.59 M TWD, representing a -31.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity TaiRx since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's TaiRx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — TaiRx

All Key Metrics — TaiRx